PMID- 37056822
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230415
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 15
IP  - 3
DP  - 2023
TI  - Effectiveness and safety of mono-anlotinib mono therapy or in combination with 
      chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center 
      retrospective study.
PG  - 1973-1981
AB  - OBJECTIVE: To evaluate the clinical efficacy of mono-anlotinib therapy by itself 
      or in combination with chemotherapy in platinum-resistant recurrent ovarian 
      cancer (PROC). METHODS: The clinical data of 35 patients with platinum-resistant 
      recurrent ovarian cancer admitted to the First Affiliated Hospital of Anhui 
      Medical University from March 2019 to July 2020 were retrospectively analyzed. 
      All the patients received anlotinib mono- or combined chemotherapy. The 
      effectiveness and adverse events (AEs) were analyzed by RECIST1.1 and CTCAE5.0. 
      RESULTS: In the 35 patients, the median follow-up was 9.80 (95% CI: 3.83-15.77) 
      months. The median progression free survival (mPFS) achieved 6.50 (95% CI: 
      2.02-10.98) months, the objective response rate (ORR) achieved 17.14%, and 
      disease control rate (DCR) achieved 60.00%. ORR and DCR were 12.50% and 25.0% for 
      monotherapy, 18.52% and 70.37% for combined chemotherapy. The PFS of combined 
      chemotherapy was longer than that of monotherapy (log-rank P = 0.003). 
      thirty-four patients (97.14%) were in a third-line therapy or above, and their 
      ORR and DCR were 14.71% and 58.82%, respectively. Two patients discontinued 
      treatment because of intolerable AEs. No cases of grade 4-5 AEs have been 
      reported. CONCLUSION: Anlotinib had promising effectiveness and tolerable safety 
      in patients with PROC, even in patients who accepted anlotinib as a third-line or 
      above therapy or with a history of other antiangiogenic drugs.
CI  - AJTR Copyright (c) 2023.
FAU - Wu, Yue
AU  - Wu Y
AD  - Oncology Department of Integrated Traditional and Western Medicine, The First 
      Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China.
AD  - The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui 
      Medical University Hefei 230032, Anhui, China.
FAU - Li, Ping
AU  - Li P
AD  - Oncology Department of Integrated Traditional and Western Medicine, The First 
      Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China.
AD  - The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui 
      Medical University Hefei 230032, Anhui, China.
FAU - Zhu, Yaodong
AU  - Zhu Y
AD  - Oncology Department of Integrated Traditional and Western Medicine, The First 
      Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China.
AD  - The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui 
      Medical University Hefei 230032, Anhui, China.
FAU - Zhang, Fengli
AU  - Zhang F
AD  - Oncology Department of Integrated Traditional and Western Medicine, The First 
      Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China.
AD  - The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui 
      Medical University Hefei 230032, Anhui, China.
FAU - Su, Li
AU  - Su L
AD  - Oncology Department of Integrated Traditional and Western Medicine, The First 
      Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China.
AD  - The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui 
      Medical University Hefei 230032, Anhui, China.
FAU - Ye, Yingquan
AU  - Ye Y
AD  - Oncology Department of Integrated Traditional and Western Medicine, The First 
      Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China.
AD  - The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui 
      Medical University Hefei 230032, Anhui, China.
FAU - Huang, Yi
AU  - Huang Y
AD  - Anhui University of Traditional Chinese Medicine Hefei 230038, Anhui, China.
FAU - Zhang, Mei
AU  - Zhang M
AD  - Oncology Department of Integrated Traditional and Western Medicine, The First 
      Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China.
AD  - The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui 
      Medical University Hefei 230032, Anhui, China.
LA  - eng
PT  - Journal Article
DEP - 20230315
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC10086922
OTO - NOTNLM
OT  - Angiogenesis inhibitors
OT  - anlotinib
OT  - combination drug therapy
OT  - ovarian epithelial carcinoma
OT  - ovarian neoplasms
COIS- None.
EDAT- 2023/04/15 06:00
MHDA- 2023/04/15 06:01
PMCR- 2023/03/15
CRDT- 2023/04/14 02:34
PHST- 2022/11/21 00:00 [received]
PHST- 2023/02/09 00:00 [accepted]
PHST- 2023/04/15 06:01 [medline]
PHST- 2023/04/14 02:34 [entrez]
PHST- 2023/04/15 06:00 [pubmed]
PHST- 2023/03/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2023 Mar 15;15(3):1973-1981. eCollection 2023.